Gain Therapeutics, Inc. (GANX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Income tax | 141,205 | 10,994 | 1,209 | |
| Interest income (expense), net | - | 105,405 | 84,531 | |
| Research and development | 2,758,973 | 2,621,722 | 4,437,631 | |
| General and administrative | 2,330,553 | 1,837,242 | 3,745,193 | |
| Total operating expenses | 5,089,526 | 4,458,964 | 8,182,824 | |
| Loss from operations | -5,089,526 | -4,458,964 | -8,182,824 | |
| Interest income, net | 42,568 | - | - | |
| Foreign exchange (loss) gain, net | -620,924 | -121,139 | -43,576 | |
| Loss before income tax | -5,667,882 | -4,474,698 | -8,141,869 | |
| Net loss | -5,809,087 | -4,485,692 | -8,143,078 | |
| Earnings per share, basic | -0.19 | -0.17 | -0.42 | |
| Earnings per share, diluted | -0.19 | -0.17 | -0.42 | |
| Weighted average number of shares outstanding, basic | 30,341,523 | 26,531,747 | 19,215,582 | |
| Weighted average number of shares outstanding, diluted | 30,341,523 | 26,531,747 | 19,215,582 | |